Payment overview · 2025
General Payments
$979.33
41 reported records · 17 companies
Healthcare provider profile · identity verified
Jane L Emerick, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · WESTERVILLE, OH · NPI 1053307066
Verified facts
What the public records show
CMS Open Payments records show Jane L Emerick, M.D. received $979.33 in general payments during 2025 across 41 reported records.
Smith+Nephew, Inc. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Isentress by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $225.27 | 23.0% | 11 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $129.06 | 13.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $120.09 | 12.3% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $100.91 | 10.3% | 4 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $63.83 | 6.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.45 | 4.8% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $45.06 | 4.6% | 2 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.65 | 4.6% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.73 | 4.4% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $32.33 | 3.3% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $21.44 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.62 | 2.1% | 1 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $20.54 | 2.1% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $18.83 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.02 | 1.7% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $15.63 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.87 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $979.33 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $129.06 | 1 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $129.06 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $123.57 | 6 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $120.09 | 6 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $100.91 | 4 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $71.69 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $63.83 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $63.83 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $47.45 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $47.45 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $47.45 | 2 | 2025 |
Source payment records
|
|||||
| VIBATIV Normalized: vibativ |
Drug | Cumberland Pharmaceuticals, Inc. | $44.65 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| PREVYMIS Normalized: prevymis |
Drug | Merck Sharp & Dohme LLC | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $32.33 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $32.33 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ Normalized: aquacel ag |
Device | ConvaTec Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| REGRANEX Normalized: regranex |
Drug | Smith+Nephew, Inc. | $9.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vancomycin Hcl | Vancomycin Hcl | 198 | 25 |
| Cephalexin | Cephalexin | 119 | 55 |
| Cefuroxime | Cefuroxime Axetil | 90 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 46 |
| Fluconazole | Fluconazole | 74 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 32 |
| Ceftriaxone | Ceftriaxone Sodium | 55 | suppressed |
| Ertapenem | Ertapenem Sodium | 52 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 24 |
| Mupirocin | Mupirocin | 44 | 26 |
| Azithromycin | Azithromycin | 42 | 13 |
| Meropenem | Meropenem | 39 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 38 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 36 | suppressed |
| Prednisone | Prednisone | 36 | 11 |
| Isentress | Raltegravir Potassium | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 24 |
| Daptomycin | Daptomycin | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 24 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 32 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 21 |
| Metronidazole | Metronidazole | 29 | 11 |
| Acyclovir | Acyclovir | 26 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Trimethoprim | Trimethoprim | 25 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 14 | suppressed |
| Ceftazidime | Ceftazidime | 14 | suppressed |
| Lamivudine | Lamivudine | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Colistimethate | Colistin (Colistimethate Na) | 13 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 13 | suppressed |
| Nevirapine | Nevirapine | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $979.33 · 41 records | Smith+Nephew, Inc. | ACTIV.A.C., AQUACEL AG+, AVYCAZ, CABENUVA, COLLAGENASE SANTYL, CUTAQUIG, Cresemba, DOVATO, EMBLAVEO, Fetroja, Flexitouch Plus, GRAFIX PL, KRYSTEXXA, Kerecis GraftGuide, Kerecis SurgiClose, Kimyrsa, NUZYRA, Nimbl, Orbactiv, PANZYGA, PREVYMIS, PROMOGRAN PRISMA, REGRANEX, Rezzayo, STRAVIX PL, TEFLARO, VIBATIV, VOWST, ZERBAXA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error